Calithera Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CALA Over the counter 2834 http://www.calithera.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Calithera Biosciences Inc

Biotech company Calithera plans its own death. Will others follow? - Jan 10th, 2023 4:02 pm
Calithera Biosciences Stock Nosedives On Complete Liquidation, Dissolution - Jan 9th, 2023 3:18 pm
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution - Jan 9th, 2023 1:00 pm
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update - Nov 14th, 2022 9:05 pm
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 - Nov 8th, 2022 9:30 pm
KalVista (KALV) Stock Continues to Decline: Here's Why - Oct 6th, 2022 5:50 pm
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer - Oct 3rd, 2022 11:00 am
Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug - Sep 26th, 2022 4:09 pm
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal - Sep 22nd, 2022 2:23 pm
3 Penny Stocks With Surprisingly Superior Fundamentals - Sep 9th, 2022 7:14 pm
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 6th, 2022 8:05 pm
This Small Cap Cancer Stock Gets An Upgrade And Price Target Bump On 'Clinical Programs Progress' - Aug 29th, 2022 7:52 pm
Companies Like Calithera Biosciences (NASDAQ:CALA) Could Be Quite Risky - Aug 16th, 2022 12:15 pm
Calithera Biosciences (CALA) Q2 2022 Earnings Call Transcript - Aug 16th, 2022 3:00 am
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights - Aug 15th, 2022 8:05 pm
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022 - Aug 8th, 2022 8:05 pm
What Is a Reverse Stock Split and How Does It Work? - Jul 28th, 2022 4:42 pm
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences - Jul 13th, 2022 8:01 pm
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer - Jul 6th, 2022 8:01 pm
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma - Jun 23rd, 2022 8:05 pm